While a prominent role of MCL1 in chemoresistant cancer has been described in multiple studies, the loss of sensitivity to BCL2/BCL-XL inhibitors observed here may be more controversial and potentially limited to neuroblastoma. This evidence concerns the gene MCL1 and cancer.